



PATENT APPLICATION
File No: 99-16D3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of : Julia E. Novak, Scott R. Presnell, Cindy A. Sprecher, Donald C. Foster,
Richard D. Holly, Jane A. Gross, Janet V. Johnston, Andrew J. Nelson,
Stacey R. Dillon, Angela K. Hammond

Serial No. : 10/787,442

Group Art Unit : 1647

Examiner :

Filed : February 26, 2004

For : CYTOKINE ZALPHA11 LIGAND FUSION PROTEINS

Date Submitted : July 27, 2006

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the examination of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

In accordance with 37 C.F.R. 1.97, the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been conducted, nor shall it be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

The references are listed in PTO form 1449 which is in accordance with the requirements of M.P.E.P. 609. Applicants believe that their invention as claimed is patentable over the references.

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the Undersigned if there are any questions concerning this paper or the attached references.

Pursuant to the provisions of M.P.E.P. §609, Applicants further request that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

It is believed that no fee is due, as this Supplemental Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event that a fee is due, please charge any fee or credit any overpayment to Deposit Account No. 26-0290.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Deborah A. Sawislak". The signature is written in a cursive, flowing style.

Deborah A. Sawislak
Registration No. 37,438

FORM PTO 1449
(REV 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

File No. 99-16D3

Serial No.
10/787,442

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant(s):

Julia E. Novak, Scott R. Presnell, Cindy
A. Sprecher, Donald C. Foster, Richard
D. Holly, Jane A. Gross, Janet V.
Johnston, Andrew J. Nelson, Stacey R.
Dillon, Angela K. HammondFiling Date:
February 26, 2004

Group: 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	Name	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	10/456,262	06-06-03	Nelson et al.			
	A2	11/285,970	11/23/05	Yee			
	A3	11/346,580	02-02-06	Novak et al.			
	A4	2004-0009150	01-15-04	Nelson et al.			
	A5	2004-0110932	06/10/04	Novak et al.			
	A6	2005-0095223	05-05-05	Sivakumar et al.			
	A7	2005-0244930	11/03/05	Presnell et al.			
	A8	2005-0265966	12-01-05	Kindsvogel et al.			
	A9	2006-0134754	06/22/06	Chan et al.			
	A10	6,307,024	10/23/01	Parrish et al.			
	A11	6,605,272	08/12/03	Dillon et al.			
	A12	6,686,178	02-03-04	Dillon et al.			
	A13	6,929,932	08/16/05	Presnell et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial		DOCUMENT NUMBER	Date	COUNTRY	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A14	04/032857	04/22/04	WO			
	A15	05/037306	04/28/05	WO			
	A16	99/61617	12/02/99	WO			
	A17	04/112703	12/29/04	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Patents, etc.)

	A18		Hill et al., "Cytokines: promoters and dampeners of autoimmunity," <i>Current Opinion in Immunology</i> , <i>Current Biology LTD</i> 14(6):791-797, 2002.
	A19		Clegg et al., "Therapeutic Opportunities for IL-21," <i>European Cytokine Network</i> vol. 14, no. Supplement 3, 2003.
	A20		Nelson, et al., "Interleukin 21 has anti-tumor activity in animal models without the toxicity of IL-2," <i>Procedures of the American Association for Cancer Research Annual Meeting</i> , vol. 44, July 2003.
	A21		Funaro et al., "Monoclonal antibodies and therapy of human cancers," <i>Biotechnology Advances</i> , Elsevier Publishing Barking, GB vol. 18 no. 5, 2000.

Examiner

Date considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.